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1. Introduction
  Adoptive immunotherapy using antigen-specific T cells is 
a promising strategy to treat a variety of infectious diseases 
and cancer. Although adoptive immunotherapy with tumor-
specific cytotoxic T lymphocytes (CTLs) has been widely 
studied and been successfully used to treat certain cancers, 
obstacles still have to be overcome. Previous studies of 
adoptive immunotherapy with tumor-specific CTLs have 
achieved successful results in in vitro experiments, but the 
effectiveness is not as good as in vivo experiments and in 
clinical trials[1-3]. These problems can mainly be explained 
by the fact that the activities of adoptive CTLs are inhibited 
in animal and human hosts, preventing the effective 
clearance of tumor cells[4,5]. Therefore, increasing the anti-
tumor activity of tumor-specific CTLs is key to the success 
of specific adoptive immunotherapy of tumors[6]. 
Objective: To develop a novel artificial antigen-presenting system for efficiently inducing 
melanoma-specific CD8+CD28+ cytotoxic T lymphocyte (CTL) responses. Methods: Cell-sized 
Dynabeads襅M-450 Epoxy beads coated with H-2Kb:Ig-TRP2180-188 and anti-CD28 antibody 
were used as artificial antigen-presenting cells (aAPCs) to induce melanoma-specific CD8+CD28+ 
CTL responses with the help of IL-21 and IL-15. Dimer staining, proliferation, ELISPOT, and 
cytotoxicity experiments were conducted to evaluate the frequency and activity of induced 
CTLs. Results: Dimer staining demonstrated that the new artificial antigen-presenting system 
efficiently induced melanoma TRP2-specific CD8+CD28+ CTLs. Proliferation and ELISPOT assays 
indicated that the induced CTLs rapidly proliferate and produce increased IFN-毭 under the 
stimulation of H-2Kb:Ig-TRP2-aAPCs, IL-15, and IL-21. In addition, cytotoxicity experiments 
showed that induced CTLs have specific killing activity of target cells. Conclusions: The new 
artificial antigen-presenting system including aAPCs plus IL-21 and IL-15 can induce a large 
number of antigen-specific CD8+CD28+ CTLs against the melanoma. Our study provides evidence 
for a novel adoptive immunotherapy against tumors. 
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  IL-21 and IL-15, members of the common cytokine 
receptor gamma-chain family, play an important role in the 
proliferation and activity of CD8+ T cells. IL-21 is mainly 
produced by activated CD4+ T cells and can greatly promote 
the proliferation and differentiation of CD8+ T cells[7], and 
thus enhance the cell toxicity of CTLs[8]. IL-15 can also 
promote the proliferation of naive and memory CD8+ T 
cells[9]. Previous studies reported that the combination of IL-
21 and IL-15 synergistically enhanced the biological activity 
of CD8+ T cells, and induced memory CD8+ CTLs with high 
levels of CD28[10]. 
  It has been shown that artificial antigen-presenting cells 
(aAPCs) can overcome the shortcomings of the conventional 
method in expanding antigen-specific CTLs[11]. aAPCs 
that are constructed by presenting a combination of MHC-
peptide complexes and costimulatory molecules on the 
surface of the carrier mimic the dual signaling mechanisms 
necessary for T cell activation. aAPCs can effectively 
activate antigen-specific CTLs and induce CTL responses 
with high efficiency and feasibility[12,13]. We have previously 
developed several novel aAPC systems to induce tumor-
specific CD8+ CTLs[12,13], but the biological activity of 
induced CD8+ CTLs needs to be further improved to ensure 
high activity in the human body.
  Recent studies have demonstrated that CD8+ CTLs with 
high CD28 expression survived longer and had increased 
proliferation rates[14,15]. In addition, Bloom et al reported 
that the peptide SVDFFVWL (TRP2180-188) from the TRP2 
protein is H-2Kb restricted and is a mouse melanoma-
specific peptide[16]. Thus, in this study, we used the mouse 
melanoma-specific peptide TRP2180-188 as a target to develop 
an artificial antigen presenting system to induce melanoma-
specific CD8+CD28+ CTLs for the potential immunotherapy of 
melanoma. Cell-sized microspheres coated with complexed 
H-2Kb:Ig-TRP2 and anti-CD28 antibody were used as 
aAPCs to induce melanoma-specific and H-2Kb-restricted 
CTLs under the stimulation of IL-21 and IL-15. Our study 
indicates that aAPCs under the stimulation of IL-21 and IL-
15 can efficiently induce melanoma-specific CD8+CD28+ 
CTLs with high tumor-specific activity. 
2. Materials and methods
2.1. Cell lines and cell culture
   The B16 melanoma cell line was derived from a 
spontaneous melanoma in a C57BL/6 mouse and was 
cultured in our laboratory. The mouse hepatocellular 
carcinoma cell line H22 was purchased from Shanghai 
FMGBio Tech Co., Ltd. The dendritic cell line, DC2.4 was 
cultured in our laboratory. All the cells were cultured in 
complete RPMI 1640 or Dulbecco’s modified Eagle medium 
(DMEM, HyClone, Thermo) containing 10% Fetal Bovine 
Serum (FBS) (Hyclone, Thermo), 100 毺g/mL streptomycin 
and 100 IU/mL penicillin at 37 曟, 5% CO2.
2.2. Polypeptides
  The H-2Kb-restricted and lung cancer-specific antigenic 
peptide Mut1 (amino acid: 52-59, N-FEQNTAQP-COOH[17]), 
and the H-2Kb-restricted and melanoma-specific antigenic 
peptide TRP2 (amino acid: 180-188, N-SVYDFFVWL-
COOH) were chemically synthesized by Nanjing GenScript 
Corporation with a purity of greater than 95%.
2.3. Antibodies and FACS 
  Purified hamster anti-mouse CD28 antibody and PE-
labeled CD8 monoclonal antibody were purchased from 
(BD pharmingen, San Jose, USA). FITC-labeled mouse IgG1 
monoclonal antibody was purchased from (Biolegend, San 
Diego, CA, USA). PE-Cy5 labeled mouse CD28 monoclonal 
antibody was purchased from (eBioscience, CA, USA). 
Labeled cells were analyzed on a Beckman Coulter flow 
cytometer and the data was analyzed using EXPO32 analysis 
software (Beckman Coulter, USA). 
 
2.4. Preparation of aAPCs
  100 毺g/mL of TRP2 antigen or control peptide Mut1 were 
incubated with 20 毺g/mL of recombinant soluble Dimeric 
mouse H-2Kb:Ig Fusion protein (BD Bioscience), at 37 曟 
overnight to generate H-2Kb:Ig-TRP2 complexes and 
H-2Kb:Ig-Mut1 complexes. Artificial beads (Dynabeads
襅M-450 Epoxy, Invitrogen, Norway) were incubated 
with H-2Kb:Ig-TRP2 complexes and anti-mouse CD28 
monoclonal antibody (2 毺g/mL) at 4 曟  for 1 h to make H-2 
K
b:Ig:TRP2-aAPCs. The control peptide Mut1 was prepared 
in the same way to make H-2Kb: Ig-Mut1-aAPCs that were 
used as a control.
2.5. Inducing T cell activation
  4-6 weeks female C56B/L mice (H-2Kb) were purchased 
from Beijing Unicom Lihua. Mouse splenic lymphocytes 
were isolated using lymphocyte separation medium (EZ-
SepTM, DAKEWE) and cultured in complete RPMI 1640 at 
37 曟 under 5% CO2. Cells were seeded into 24-well plates 
at a density of 3暳10
6-4暳10
6 cells/mL and co-cultured with 
H-2Kb: Ig-TRP2-aAPCs or H-2Kb: Ig-Mut1-aAPCs (the 
ratio of cells and aAPCs was 10:1) in the presence of rmIL-
21 (25 ng/mL, R & D, USA) and/or rmIL-15 (25 ng/mL, R & D, 
USA)[18]. The cells were fed every 3-4 days and aAPCs were 
replaced once every seven days.
 
2.6. Detection of TRP2-specific CD8+CD28+ T cells
  Isolated mouse splenic lymphocytes were co-cultured with 
artificial H-2Kb:Ig-TRP2-aAPCs or H-2Kb:Ig-Mut1-aAPCs 
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in the presence of rmIL-21 and/or rmIL-15 for 1 week. Cells 
were collected and analyzed by FACS to detect the dimer 
and CD8+CD28+ cell frequency.
2.7. Isolation of CD8+ T cells and cell proliferation assays
  CD8+ T cells were positively selected from mouse splenic 
lymphocytes using CD8 antibody coated dynabeads 
(Invitrogen, Carlsbad, CA, USA) and microbeads (Miltenyi 
Biotec). The purity of selected CD8+ T cell populations was 
> 95%, as measured by FACS analysis. The proliferation of 
CD8
+ T cells was measured by carboxyfluorescein diacetate 
succinimidyl ester (CFSE) as described previously[19,20]. 
Briefly, selected CD8+ T cells were incubated with 5 毺mol/L
of CFSE at 37 曟 for 10min, then washed three times with 
RPMI 1640 containing 10% FBS. 2暳10
6/mL of CD8+ T cells 
were plated into 12-well plates and co-cultured with 
H-2Kb:Ig-TRP2-aAPCs at 37 曟 with 5 % CO2 in the presence 
of rmIL-21 and/or rmIL-15. On the third day, cells were 
analyzed by FACS and the proliferation index was analyzed 
by ModFit LT software (Beckman Coulter, USA).
2.8. ELISPOT assay
  The ELISPOT protocol was modified according to the 
following[21]. The CD8+ T cells were stimulated and co-
cultured with H-2Kb:Ig-TRP2-aAPCs in the presence of 
rmIL-21 and/or rmIL-15 for one week, then cells were 
seeded at 1暳10
6/well and co-cultured with H-2Kb:Ig-TRP2-
aAPCs or H-2Kb:Ig-Mut1-aAPCs in a 96-well plate coated 
with mouse IFN-毭 antibody (DAKEWE), at 37 曟 for 16 h. 
The spots were quantified using an ELISOPT counter, and 
analysed with the Immunospot count  software, according to 
the manufacturer’s instruction (CTL Technologies).
2.9. Cytotoxicity assay
  The cytotoxicity of TRP2-specific CD8+CD28+ T cells was 
measured by Prodium Iodide (PI) staining and FACS[22]. The 
target cells B16, DC2.4 and H22 were washed twice with 
0.1% BSA-PBS and stained with PKH26 dye (Sigma Aldrich) 
at room temperature for 4 min, in accordance with the 
manufacturer’s instruction. TRP2-specific CD8+CD28+ T cells 
(effector cells) and PKH26 positive cells (target cells) were 
plated in 48-well plates according to the effector:target ratio 
(40:1, 20:1, 10:1, 5:1) and co-cultured at 37 曟 with 5% CO2 
for 6 h. Cells were collected and stained using PI (Roche) 
at room temperature for 15 min. The stained cells were 
analyzed by FACS and the data were analyzed with EXPO32 
software. The target cell apoptosis rate was defined in PKH26 
positive cells. Data are expressed as the percent specific 
release, calculated as follows: [(experimental release - 
spontaneous release)/(100 - spontaneous release )] 暳100.
2.10.  Statistical analysis
  The data were showed as mean暲standard deviation and 
analyzed using SPSS 17.0 software  (SPSS Inc, Chicago, IL) 
or the use of GraphPadPrism 5 software (GraphPad, San 
Diego, CA). Continuous variables were compared by one-
way analysis of variance (ANOVA). The value of  P <0.05 was 
considered statistically significant.
3. Results
3.1. Effect of novel artificial antigen-presenting system 
on high frequencies of CD8+CD28+ T cells specific to the 
melanoma peptide TRP2
  Dimer staining was used to investigate whether the 
novel artificial antigen-presenting system generated high 
frequencies of antigen-specific CD8+CD28+ T cells. As shown 
in Figure 1, the histograms show the rate of H-2Kb:Ig-TRP2-
specific CD8+CD28+ T cells in the experimental group treated 
with a combination of H-2Kb:Ig-TRP2-aAPCs with IL-15 
and IL-21 was significantly higher than the other groups 
(P< 0.01). These results indicate that H-2Kb:Ig-TRP2-aAPCs 
plus IL-21 and IL-15 can efficiently induce high frequencies 
of TRP2-specific CD8+CD28+ T cells . 
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Figure 1. Effect of novel artificial antigen-presenting system on high 
frequencies of CD8+CD28+ T cells specific to the melanoma peptide 
TRP2.
The rate of H-2Kb:Ig-TRP2-specific CD8+CD28+ T cells in the 
experimental group treated with a combination of H-2Kb:Ig-TRP2-
aAPCs with IL-15 and IL-21 was 4.49%.** P < 0.01 compared with the 
control groups.
3.2. Effect of induced-T cells by H-2Kb:Ig-TRP2-aAPCs 
plus IL-21 and IL-15 on proliferation ability of T cells
   CFSE staining was used to evaluate the proliferation 
ability of T cells induced by different factors including 
H-2Kb:Ig-TRP2-aAPCs, H-2Kb:Ig-TRP2-aAPCs plus IL-15, 
H-2Kb:Ig-TRP2-aAPCs plus IL-21, and H-2Kb:Ig-TRP2-
aAPCs plus IL-21 and IL-15. As shown in Figure 2A-D, T 
cells induced by the combination of H-2Kb:Ig-TRP2-aAPCs 
with IL-15 and IL-21 demonstrated the most proliferation, 
3.92, which was significantly higher than proliferation in the 
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other groups. The Figure 2E histograms show similar results 
(P<0.05). These results indicate that the induced-T cells by 
H-2Kb:Ig-TRP2-aAPCs plus IL-21 and IL-15 proliferated 
more readily than control groups. 
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Figure 2. Effect of induced-T cells by H-2Kb:Ig-TRP2-aAPCs plus 
IL-21 and IL-15 on proliferation ability of T cells. 
(A). The proliferation index of the H-2Kb:Ig-TRP2-aAPCs without 
cytokines group was 1.77. (B). The proliferation index of the H-2Kb:Ig-
TRP2-aAPCs plus IL-21 group was 2.87. (C). The proliferation index of 
the H-2Kb:Ig-TRP2-aAPCs plus IL-15 was 3.37. (D). The proliferation 
index of the H-2Kb:Ig-TRP2-aAPCs plus cytokines IL-15 and IL-21 
group was 3.92. * P < 0.05 compared with the control group.
3.3. Effect of induced-T cells by H-2Kb:Ig-TRP2-aAPCs 
plus IL-21 and IL-15 on levels of IFN-毭
  We used ELISPOT assays to measure the quantity of the 
induced-T cells that produced IFN-毭 under continuous 
stimulation with H-2Kb:Ig-TRP2-aAPCs or H-2Kb:Ig-Mut1-
aAPCs. As shown in Figure 3A, the number of the induced-T 
cells by H-2Kb:Ig-TRP2-aAPCs plus IL-21 and IL-15 
that produced IFN-毭 under continuous stimulation with 
H-2Kb:Ig-TRP2-aAPCs was 160, which was significantly 
higher than other groups. The histograms (Figure 3B) show 
the mean and standard deviation of the numbers of the 
induced-T cells under the stimulation of different molecules 
and was similar to the results shown in Figure 3A (P < 0.05). 
These results show that the induced-T cells by H-2Kb:Ig-
TRP2-aAPCs plus IL-21 and IL-15 produced IFN-毭 at high 
levels under the stimulation of H-2Kb:Ig-TRP2-aAPCs in 
the novel artificial antigen presenting system. 
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Figure 3. Effect of induced-T cells by H-2Kb:Ig-TRP2-aAPCs plus 
IL-21 and IL-15 on levels of IFN-毭. 
(A). Comparison of the quantity of cells producing IFN-毭 between 
each of the groups. The number of the induced-T cells by H-2Kb:Ig-
TRP2-aAPCs plus IL-21 and IL-15 producing IFN-毭 was 180, higher 
than the other controls (21, 105, 80, 53 respectively). These data are 
based on triplicate experiments. (B). The mean and standard deviation 
of the quantity of T cells producing IFN-毭 from each group. * P< 0.05 
compared to the control group.
3.4. Specific toxicity activities of induced-T cells by 
H-2Kb:Ig-TRP2-aAPCs plus IL-21 and IL-15
  Cytotoxicity experiments were conducted to test whether 
the induced-T cells by H-2Kb:Ig-TRP2-aAPCs plus IL-
21 and IL-15 had specific cytotoxic activities. As shown in 
Figure 4, the antigen-specific ability to kill B16 target cells 
was significantly higher when compared to control target 
cells, DC2.4 and H22 (P<0.05). These results indicate that the 
induced-T cells by H-2Kb:Ig-TRP2-aAPCs plus IL-21 and 
IL-15  have antigen-specific cytotoxic activities. 
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Figure 4. Specific toxicity activities of induced-T cells by H-2Kb:Ig-
TRP2-aAPCs plus IL-21 and IL-15. 
The experiments were repeated three times. * P<0.05. 
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4. Discussion
   CD8+ CTLs play an important role in the adaptive immune 
response, especially in anti-tumor and anti-infection 
immunity[23], which makes them a promising candidate 
for adoptive immunotherapy. However, long-term studies 
found that adoptive immunotherapy with CD8+ CTLs is often 
characterized by poor persistence of the transferred T cells 
and limited effector responses, which has limited their 
usage. In this study, we developed a novel artificial antigen-
presenting system to induce highly efficient tumor specific 
CTLs. This artificial antigen-presenting system uses aAPCs 
together with IL-21 and IL-15 to induce melanoma-specific 
CD8
+
CD28
+ CTLs as a potential approach for immunotherapy 
of melanoma. 
  aAPCs are constructed with artificial materials (such 
as beads, liposomes, latex microspheres, etc.) or gene-
transfected cells (such as tumor cells, insect cells, etc.) that 
are used as carriers and coated with molecules that can 
stimulate T cell activation. T cells can be activated in vitro 
and in vivo by aAPCs that mimic T cell activation signals. 
In addition, aAPCs can be used in adoptive immunotherapy 
against tumor and infectious diseases by modifying the 
types and quantity of stimulatory molecules on the surface 
of aAPCs. They can also be used in the study of antigen-
presenting and T cell activation signals. aAPCs can easily 
be prepared and preserved, and manual regulation of 
the types and quantity of stimulatory molecules on the 
surface of aAPCs make them an ideal tool for anti-tumor 
immunotherapy. In addition, aAPCs can induce and 
stimulate the proliferation of antigen-specific CTLs in vitro, 
which helps overcome limitations of conventional methods 
which use peptide-loaded dendritic cells for inducing 
antigen-specific CTLs[24]. Melanoma is one type of cancer 
that is sensitive to immunotherapy. A large number of 
melanoma-associated antigen epitopes have been identified 
and characterized, suggesting aAPCs may be a promising 
therapeutic tool in adoptive immunotherapy of melanoma. 
In this study, we successfully developed H-2Kb-Ig:TRP2-
aAPCs, that are specific to the melanoma-specific antigen 
peptide TRP2180-188. 
  In immune responses, CD28 molecules are highly expressed 
on the surface of naive T cells. Binding of CD28 with B7 
molecules initiates the second signal of T cell activation[25]. 
However, CD28 expression on naive CD8+ T cells gradually 
decreases after antigen stimulation, resulting in increased 
numbers of CD8+CD28 T cells over time[18]. In clinical studies 
of patients with ulcerative colitis, the number of CD8+CD28- T 
cells was higher than CD8+CD28+ T cells[20]. In addition, some 
studies observed that naive T cells in the body decrease 
with increased age. Due to the absence of CD28 molecules 
that are critical for starting the second signal, these naive 
T cells gradually change to become incompetent memory 
lymphocytes, such as CD8+CD28- T cells[18,26,27]. Recently, 
studies have shown that high levels of CD28 on CD8+ CTLs 
can increase the proliferation and survival of CTLs in the 
body[14,15]. Thus, adoptive immunotherapy targeting CD28 
on CD8+ CTLs might be better than the traditional adoptive 
immunotherapy based on CD8+ CTLs alone. In this study, we 
confirmed that our novel artificial antigen presenting system 
efficiently induced melanoma-specific CD8+CD28+ CTLs that 
specifically killed tumor cells. 
  IL-21 can induce CD8+ T cell proliferation and 
differentiation[28,29], promote the proliferation of memory T 
cells[14], activate NK cells[30], and enhance CTL toxicity[10]. 
Unlike IL-2, which regulates the function of memory T cells 
by inducing regulatory T cells (Tregs), IL-21 can inhibit the 
proliferation of Tregs to ultimately reverse the inhibitory 
effect of Tregs on CD8+ T cells. The proliferation of CD8+ 
T cells can cause tumor cell-mediated death by CD8+ T 
cells[31,32]. Therefore, IL-21 may have promising application 
for cancer immunotherapy. Numerous studies suggest that 
CTLs and NK cells play an important role in anti-tumor 
immunity mediated by IL-21. Kaka et al confirmed that 
T cells in which the IL-21 gene was overexpressed were 
able to promote the proliferation of central memory tumor-
specific CD8+ CTLs and significantly extend the lifespan 
of the tumor-specific central memory CTLs[33]. This study 
suggests that IL-21 may be associated with the central 
memory component of the immune system. IL-15 and IL-
21 are both members of the common cytokine gamma-
chain receptor family. IL-15 has been proven to promote 
the proliferation of naive CD8+ T cells and memory CD8+ 
T cells, and it can maintain the number and function of 
naive CD8+ T cells in humans and mice[9,20]. However, IL-15 
downregulates the expression of CD28 on CD8+ T cells[10,18]. 
On the contrary, IL-21 promotes the proliferation of naive 
CD8
+ T cells and plays an important role in maintaining 
the long-term activity and function of CD8+ T cells. One 
study demonstrated that IL-21 prevented the aging of 
CD8
+ T cells with increased age in humans[27]. In addition, 
IL-21 prevented the ability of IL-15 to downregulate the 
expression of CD28 on naive CD8+ T cells or memory CD8+ 
T cells[18,19]. Therefore, the combination of IL-15 and IL-21 
could significantly increase the proliferation and cytotoxic 
function of naive or memory CD8+ T cells. Their combination 
can also neutralize the negative effects caused by IL-
15 regarding the downregulation of CD28. Studies have 
demonstrated that low doses of IL-15 and IL-21 promote the 
proliferation of CD28+ cells[10,18]. Our study further confirms 
that the combination of IL-15 and IL-21 efficiently induced 
the proliferation of melanoma-specific CD8+CD28+ CTLs 
mediated by H-2Kb-Ig:TRP2-aAPCs.
  In conclusion, we developed a novel artificial antigen-
presenting system that employs melanoma-specific 
aAPCs plus IL-21 and IL-15 to efficiently induce efficient 
responses from melanoma-specific CD8+CD28+ T cells. 
Our results demonstrate that the induced melanoma-
specific CD8+CD28+ CTLs express high levels of IFN-毭 and 
proliferate at higher rates than regular CTLs. This novel 
system provides an alternative approach for the generation 
of tumor-specific CD8+CD28+ CTLs and may be useful for the 
adoptive immunotherapy against melanoma. 
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